BioNTech's Cancer Pipeline Has Never Been More Impressive, So Why Is the Stock Languishing at 79 Euros?
18.06.2026 - 22:34:01 | boerse-global.de
BioNTech’s management kicked off a $1 billion share buyback on 8 June, sending an unmistakable signal that they believe the market has gone too far in punishing the stock. Yet the shares barely stirred, continuing to trade around €79 — roughly 25% below the January high. The disconnect is stark: the biotech group’s oncology pipeline is expanding at a pace rarely seen in the sector, and its cash hoard tops €16.8 billion. But investors remain fixated on two overhangs: the looming departure of founders Ugur Sahin and Özlem Türeci at the end of 2026, and a widening revenue gap as COVID vaccine sales fade.
The founder exit casts a long shadow. When Sahin and Türeci announced they would leave to start a new mRNA venture in March, the stock cratered more than 20% in a single day. That initial panic was understandable — leadership transitions always inject uncertainty. But the sell-off has since taken on a life of its own. The supervisory board is already hunting for successors, and a binding contract with the founders’ new company is expected by the end of June. In other words, the uncertainty has an expiration date, and it is drawing closer. The market, however, seems to be pricing in a worst-case scenario that ignores the underlying progress.
That progress was on full display at the ASCO conference in late May. BioNTech presented data on two oncology candidates that underscore its transformation from a one-product COVID player into a multi-asset cancer company. Pumitamig showed encouraging anti-tumor activity in non-small cell lung cancer, while Gotistobart delivered meaningful responses in heavily pretreated ovarian cancer patients. One detailed readout from the PRESERVE-004 study revealed a curious dose-response: the lower 1 mg/kg dose produced a median overall survival of 18.9 months, compared with 8.3 months for the higher dose. Experts note such complexity is common in oncology and does not diminish the drug’s promise.
Should investors sell immediately? Or is it worth buying BioNTech?
Beyond ASCO, the pipeline is gathering speed at a remarkable clip. BioNTech now runs over 25 advanced oncology studies — more than double the number two years ago. Six additional Phase 3 trials will start this year, bringing the total to 15. The second half of 2026 alone features seven major data readouts, covering indications from lung cancer to head-and-neck tumours. The company also plans to file its first US approval application, for Trastuzumab Pamirtecan in endometrial cancer. That is a tangible milestone, not a distant hope.
On the financial front, the picture is more sobering. First-quarter 2026 revenue slumped to €118.1 million, and the net loss came in at €531.9 million — both well below analyst estimates. The COVID vaccine Comirnaty continues to generate some revenue, but the decline is steep, and management expects no contribution from cancer drugs this year. To shore up the balance sheet, BioNTech is cutting roughly 1,860 jobs in Germany and Singapore, aiming to save €500 million annually. Cost discipline helps, but it does not replace the missing top-line growth.
Still, the company’s cash position provides ample runway. With nearly €17 billion in liquid assets against a market capitalisation of roughly €20 billion, the entire oncology pipeline is being valued at next to nothing by the market. That is an exaggeration, and analysts are calling it out. The average price target stands at around €108, implying upside of more than 35%. UBS raised its rating to Buy with a $135 target shortly after the ASCO data. Out of 19 analysts covering the stock, 14 recommend buying and none advise selling. The technical picture, meanwhile, shows the shares trapped below all major moving averages: the 200-day line sits at €85.49, about 7.5% above the current price, while the RSI of 51.7 confirms a sideways grind.
Two near-term events could break the deadlock. BioNTech will hold a business briefing on 30 June, followed by second-quarter results on 4 August. The biggest catalyst, however, would be a clear resolution to the succession question. Until then, the stock resembles a compressed spring. The clinical advances are accelerating faster than the share price reflects, and the buyback programme adds a layer of downside protection. At some point, the market will have to wake up to the reality that BioNTech’s oncology platform is no longer a side bet — it is the main event.
Ad
BioNTech Stock: New Analysis - 18 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
